Exploring the promising results of a phase II trial combining docetaxel and degarelix for metastatic prostate cancer treatment.
Exploring how a failed prostate cancer trial with mitomycin C and estramustine led to better targeted treatments for hormone-resistant metastatic prostate cancer.